| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.081 | 0.3 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.064 | 0.3 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.3 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.051 | 0.3 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.084 | 0.3 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.036 | 0.3 |